Eugene Bell Foundation

Last updated
Eugene Bell Foundation
Formation1995;29 years ago (1995)
Founder Stephen Winn Linton
Type NGO
Legal statusFoundation
PurposeHumanitarian assistance in North Korea
Headquarters Washington, D.C.
Website www.eugene-bell.org

The Eugene Bell Foundation is a U.S.-based foundation that provides medical humanitarian assistance to rural North Korea. Focusing on multidrug-resistant tuberculosis, the foundation currently sponsors 12 treatment centers, drawing patients from the western half of North Korea. The foundation primarily offers material support and medical expertise to North Korean medical staff and facilities in North Korea. The foundation is primarily financed through South Koreans and ethnic Koreans abroad. [1] According to the foundation's home-page, "Eugene Bell USA is a not-for-profit 501(c)(3) organization established in 1995 by Dr. Stephen Winn Linton". [2]

Contents

History

Stephen Linton founded the Eugene Bell Centennial Foundation in 1995 to provide teaching and research to North Korea. The foundation was named in honor of the 100th anniversary of the arrival of Eugene Bell, his ancestor, to Korea as a missionary.[ citation needed ]

From 1996 to 1998, the foundation provided grain and other food aid to North Koreans. At the request of the North Korean government, the foundation began to focus on medical aid in 1998, spending the next ten years setting up a monitored supply chain that provided diagnostic and operating room assistance to medical facilities across North Korea. [3]

By 2008, drug-resistant tuberculosis, in particular multidrug-resistant tuberculosis, had emerged as a significant and untreated threat, prompting the North Korean government to invite Eugene Bell to aid patients with the disease. As of 2014, the Eugene Bell Foundation is providing aid to 12 treatment centers in the form of medicine, diagnostic equipment, and treatment consultation. [4]

In 2013, 885 patients received care at Eugene Bell-supported multidrug-resistant tuberculosis treatment centers, a number expected to rise to 1,500 by the end of 2014.[ citation needed ]

Treating patients in North Korea

The Foundation has developed a unique medical aid model, which combines regular visits by American personnel with daily treatment by North Korean health professionals., [5] Every six months, Eugene Bell senior staff and volunteers visit each of the 12 centers receiving medical aid to gather samples from each patient and monitor progress. [6] North Korean patients are currently receiving treatment through the Eugene Bell Foundation at centers in North P'yongan Province, South P'yongan Province, Pyongyang, North Hwanghae Province, South Hwanghae Province, and Kaesong.

The medical director of the Eugene Bell Foundation, Dr. KJ Seung, published the Foundation's findings about the extent of multidrug-resistant tuberculosis in 2013. [7] The study indicates that incidence of drug resistance is much higher than previously known and recommended a rapid expansion in international aid. [8]

Relationship with the North Korean government

The Eugene Bell Foundation works closely with the North Korean Ministry of Health and relies on local North Korean nurses and doctors to provide care at treatment centers.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Tuberculosis management</span>

Tuberculosis management describes the techniques and procedures utilized for treating tuberculosis (TB).

Multiple drug resistance (MDR), multidrug resistance or multiresistance is antimicrobial resistance shown by a species of microorganism to at least one antimicrobial drug in three or more antimicrobial categories. Antimicrobial categories are classifications of antimicrobial agents based on their mode of action and specific to target organisms. The MDR types most threatening to public health are MDR bacteria that resist multiple antibiotics; other types include MDR viruses, parasites.

<span class="mw-page-title-main">Partners In Health</span> Non-profit health care organization

Partners In Health (PIH) is an international nonprofit public health organization founded in 1987 by Paul Farmer, Ophelia Dahl, Thomas J. White, Todd McCormack, and Jim Yong Kim.

TB Alliance is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.

<span class="mw-page-title-main">Stephen Winn Linton</span> American activist (born 1950)

Dr. Stephen Linton is a humanitarian and an expert on the Democratic People's Republic of Korea. He has visited North Korea over 80 times since 1979 and twice met the country's late president, Kim Il Sung, as an advisor and translator to the Rev. Billy Graham.

<span class="mw-page-title-main">Extensively drug-resistant tuberculosis</span> Tuberculosis that is resistant to the most effective drugs

Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

The National Tuberculosis Elimination Programme (NTEP), earlier known as the Revised National Tuberculosis Control Programme (RNTCP), is the Public Health initiative of the Government of India that organizes its anti-Tuberculosis efforts. It functions as a flagship component of the National Health Mission (NHM) and provides technical and managerial leadership to anti-tuberculosis activities in the country. As per the National Strategic Plan 2017–25, the program has a vision of achieving a "TB free India",with a strategies under the broad themes of "Prevent, Detect,Treat and Build pillars for universal coverage and social protection". The program provides, various free of cost, quality tuberculosis diagnosis and treatment services across the country through the government health system.

The 2007 tuberculosis scare occurred when Atlanta personal-injury lawyer Andrew "Drew" Speaker flew from Atlanta, Georgia, to Paris, France, and on to Greece and then Italy before returning on a flight from Prague, Czech Republic, to Montreal, Canada, where he crossed over the border and back into the United States while infected with multidrug-resistant tuberculosis. The Centers for Disease Control and Prevention believed at the time that Speaker was suffering from extensively drug-resistant tuberculosis (XDR-TB), but failed to inform Speaker of this worsened sickness before his travels abroad. The incident sparked a debate in Congress on the failure of federal customs agents to stop him. Upon Speaker's return to the United States, the CDC placed him under involuntary isolation using a provision of the Public Health Service Act. With this action, Speaker became the first individual subjected to a CDC isolation order since 1963.

<span class="mw-page-title-main">Bedaquiline</span> Medication used to treat tuberculosis

Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis. Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis. It is used by mouth.

<span class="mw-page-title-main">Tuberculosis in China</span>

Tuberculosis is a serious public health problem in China. China has the world's third largest cases of tuberculosis, but progress in tuberculosis control was slow during the 1990s. Detection of tuberculosis had stagnated at around 30% of the estimated total of new cases, and multidrug-resistant tuberculosis was a major problem. These signs of inadequate tuberculosis control can be linked to a malfunctioning health system. The spread of severe acute respiratory syndrome (SARS) in 2003, brought to light substantial weaknesses in the country's public health system. After the government realized the impact that the SARS outbreak had on the country, they increased leadership in their health department. After the SARS epidemic was brought under control, the government increased its commitment and leadership to tackle public health problems and, among other efforts, increased public health funding, revised laws that concerned the control of infectious diseases, implemented the world's largest internet-based disease reporting system to improve transparency, reach and speed, and started a program to rebuild local public health facilities and national infrastructure.

<span class="mw-page-title-main">Tuberculosis in India</span> Health issue in India

Tuberculosis in India is a major health problem, causing about 220,000 deaths every year. In 2020, the Indian government made statements to eliminate tuberculosis from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating the disease.

Delamanid, sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.

<span class="mw-page-title-main">William Alderman Linton</span> American missionary in Korea (1891–1960)

William Alderman Linton was an American Presbyterian missionary and Korean independence activist. He moved to Korea in 1912 and engaged in various charitable activities there.

Novosibirsk Tuberculosis Research Institute (NTRI) is a Federal State Budgetary Institution of the Ministry of Health of the Russian Federation and it specializes in the research and treatment of tuberculosis. NTRI provides the organization of TB care to the population in the regions of the Siberian and Far Eastern Federal Districts of Russia.

<span class="mw-page-title-main">Keertan Dheda</span>

Keertan Dheda MBBCh (Wits), FCP(SA), FCCP, PhD (Lond), FRCP (Lond), born in 1969, is a Professor of Mycobacteriology and Global health at the London School of Hygiene and Tropical Medicine (LSHTM) with an extra-mural joint appointment at the University of Cape Town (UCT), where he is a Professor of Respiratory Medicine.

Megan Blanche Murray is an American epidemiologist and an infectious disease physician. She is the Ronda Stryker and William Johnston Professor of Global Health in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

Jaime Bayona García is a Peruvian physician who focuses on public health and he has become a specialist in studying the epidemiology of tuberculosis. He is also known for his case studies on HIV/AIDS in Peru and other developing countries. Dr. Bayona has also done work on how public health systems should improve, in terms of providing the best approach to help the sick that cannot afford health care.

<span class="mw-page-title-main">John Alderman Linton</span> American South Korean physician (born 1959)

John Alderman Linton, also known by his Korean name Ihn Yo-han (Korean: 인요한), is an American and South Korean physician. He is the director of Yonsei University's International Health Care Center at Severance Hospital.

References

  1. Morning Edition (Radio). Educational Broadcasting System. December 17, 2009.
  2. "Eugene Bell Foundation". Eugene Bell Foundation.
  3. "History". Eugene Bell Foundation.
  4. "MDR-TB in North Korea". Partners In Health .
  5. "Seoul approves first private-level aid provision to N. Korea under new administration". Yonhap News Agency .
  6. "Giving Until it Hurts". The Washington Post . March 9, 2009.
  7. Seung, Kwonjune (2013). "The Growing Problem of Multidrug-Resistant Tuberculosis in North Korea". PLOS Medicine. 10 (7): e1001486. doi: 10.1371/journal.pmed.1001486 . PMC   3727921 . PMID   23935457.
  8. Kang, Tae-ho. "Battling Tuberculosis in both South and North Korea". The Hankyoreh .